Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,564.36
(
-0.07%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 124067

Thursday, 07/28/2011 10:26:26 AM

Thursday, July 28, 2011 10:26:26 AM

Post# of 257443
Nice call in #msg-65643941.

My concern is longer term and if HCV therapies lose the Interferon then what use would be there (in HCV).

The more immediate concern is the shortened average duration of interferon in HCV due to response guided therapy becoming the SoC. This could have an adverse effect on the demand for Promacta that is worse than the proportional reduction in interferon usage.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today